Puma Biotechnology, Inc. (NASDAQ:PBYI) CFO Maximo F. Nougues Sells 4,156 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) CFO Maximo F. Nougues sold 4,156 shares of Puma Biotechnology stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $3.70, for a total value of $15,377.20. Following the completion of the transaction, the chief financial officer now owns 162,522 shares in the company, valued at approximately $601,331.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Puma Biotechnology Stock Performance

PBYI opened at $3.66 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. Puma Biotechnology, Inc. has a 12-month low of $2.13 and a 12-month high of $7.73. The firm has a 50 day moving average of $3.59 and a two-hundred day moving average of $4.72. The firm has a market capitalization of $176.56 million, a PE ratio of 11.09 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.12. The company had revenue of $43.80 million for the quarter, compared to analyst estimates of $41.53 million. Puma Biotechnology had a net margin of 6.79% and a return on equity of 35.49%. On average, analysts anticipate that Puma Biotechnology, Inc. will post 0.22 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PBYI. StockNews.com upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, June 12th. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a research note on Monday, June 3rd.

Institutional Trading of Puma Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC lifted its holdings in Puma Biotechnology by 2.0% in the first quarter. Acadian Asset Management LLC now owns 1,956,513 shares of the biopharmaceutical company’s stock valued at $10,366,000 after acquiring an additional 39,239 shares during the period. Great Point Partners LLC purchased a new position in shares of Puma Biotechnology during the 4th quarter valued at approximately $4,734,000. Assenagon Asset Management S.A. lifted its stake in shares of Puma Biotechnology by 99.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 140,205 shares of the biopharmaceutical company’s stock valued at $457,000 after purchasing an additional 70,060 shares during the period. Citigroup Inc. purchased a new stake in Puma Biotechnology during the third quarter worth $262,000. Finally, O Shaughnessy Asset Management LLC boosted its holdings in Puma Biotechnology by 127.7% during the first quarter. O Shaughnessy Asset Management LLC now owns 77,081 shares of the biopharmaceutical company’s stock worth $409,000 after buying an additional 43,229 shares in the last quarter. 61.29% of the stock is owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.